Vertex, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher David Young
- Full Time Employees
- 1,900
- Sector
- Technology
- Industry
- Software - Application
- Address
- 2301 Renaissance Boulevard King of Prussia PA United States of America 19406
- IPO Date
- Jul 29, 2020
- CIK
- 0001806837
- Website
- vertexinc.com
- Similar Companies
- Business
- Vertex, Inc. is a technology company primarily engaged in providing tax compliance, tax automation, and related software solutions. The company offers a comprehensive suite of products and services including indirect tax software for managing sales and use tax, value-added tax (VAT), goods and services tax (GST), and other transactional taxes globally; automated tax determination software; tax data management solutions; cloud-based and on-premise tax compliance software; and integrated tax engines for enterprise resource planning (ERP) systems. Vertex’s product portfolio supports a range of industries including retail, manufacturing, financial services, and telecommunications, serving customers worldwide. The company also provides implementation, consulting, and support services to help businesses comply with evolving tax regulations. Founded in 1978 and headquartered in King of Prussia, Pennsylvania, Vertex operates internationally with offices and clients across North America, Europe, and Asia. Recently, Vertex has expanded its capabilities through strategic partnerships and new product launches aimed at enhancing its global tax compliance automation offerings. In the past 1-2 years, the company has focused on advancing its cloud-based tax solutions to better address digital tax complexities and cross-border tax compliance challenges. Vertex continues to invest in technology upgrades and integrations to support multinational corporations’ growing needs, positioning itself as a leader in the tax technology industry. These developments reflect Vertex’s commitment to innovation and broadening its market reach, underscoring its role in delivering advanced tax software solutions to help businesses navigate increasingly complex global tax landscapes. The company leverages its proprietary tax engine and extensive tax content database to deliver precise and scalable tax management solutions. Vertex is recognized for its strong customer support and technology-driven approach, targeting large enterprises and mid-market companies needing comprehensive tax automation and compliance tools. This dynamic business environment and Vertex’s expansions highlight the company’s strategic focus on maintaining leadership in the evolving tax technology sector through continuous product enhancement and global operational growth.
Madrigal Pharmaceuticals Could Become The Next Vertex
FDA Accepts Vertex's BLA for Povetacicept in IgA Nephropathy
Vertex Stock Down Nearly 8% in 3 Months: Time to Buy or Stay Cautious?
Vertex to Present at the 46th Annual William Blair Growth Stock Conference
New Vertex Research Highlights Rising Revenue Risk from IT, Tax, and Finance Misalignment
Vertex Q1 Earnings Call Highlights
Vertex: Profitability Ramps Up As Company Drives Efficiency Initiatives
Vertex, Inc. (VERX) Q1 2026 Earnings Call Transcript
Compared to Estimates, Vertex (VERX) Q1 Earnings: A Look at Key Metrics
Vertex (VERX) Tops Q1 Earnings and Revenue Estimates
Vertex Announces First Quarter 2026 Financial Results
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
These Analysts Revise Their Forecasts On Vertex Pharmaceuticals After Q1 Earnings
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Vertex Reports First Quarter 2026 Financial Results
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
A Look at Vertex Inc (VERX) After 7.2% Gain -- GF Value $35.82 vs Price $12.52
Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings
Is Vertex Pharmaceuticals' Empire in Trouble?